The key catalyst is the mid-2026 topline data from the Phase 2 Seabreeze STAT studies in asthma and COPD. Positive data could validate rademikibart's differentiated profile and unlock partnership/milestone value. The DMC's no-change recommendation is incrementally positive but not a binary catalyst. Monitor for any pre-data readout partnership announcements or Simcere's NDA progress in China.
Price Chart
Executive Summary
Connect Biopharma reported Q1 2026 results with a net loss of $19.4M ($0.34/share), widening from a $10.3M loss ($0.19/share) in Q1 2025, driven by increased R&D spend on the Phase 2 Seabreeze STAT studies. The company has $46M in cash (extending runway into H2 2027) and expects topline data from both asthma/COPD studies mid-2026, with a positive DMC interim review providing no safety concerns. The widening loss and lack of revenue growth make this a neutral-to-bearish filing for a pre-revenue biotech.
Key Financial Metrics
Key Facts
- Net loss widened to $19.4M ($0.34/share) vs $10.3M ($0.19/share) in Q1 2025
- R&D expense surged to $15.0M from $6.6M YoY due to Phase 2 Seabreeze STAT studies
- Cash and equivalents of $46.0M as of March 31, 2026, up from $44.3M at year-end 2025
- Cash runway extended into H2 2027 following $20.2M private placement closed March 31, 2026
- DMC reviewed interim analysis of Phase 2 Seabreeze STAT studies with no sample size change recommendation
- Topline data from both Phase 2 Seabreeze STAT studies expected mid-2026
- License revenue of $0.2M from Simcere agreement vs $0 in Q1 2025
- Eligible for up to ~$110M in remaining milestone payments from Simcere
Financial Impact
Net loss of $19.4M in Q1 2026 vs $10.3M in Q1 2025, a $9.1M increase (88% wider loss). Cash burn rate increased to ~$6.5M/month from ~$3.4M/month in Q1 2025.
Risk Factors
- Phase 2 topline data may fail to meet efficacy endpoints, eliminating the acute exacerbation thesis
- Cash runway only into H2 2027 — additional financing likely needed before any potential revenue
- No approved products or near-term regulatory filings in the US; single-asset risk
- Simcere's NDA for AD in China may face regulatory delays or rejection
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001835268-26-000019 |
| Document: cntb-20260512.htm | 0001835268-26-000019 |
| Document: 0001835268-26-000019-index-headers.html | 0001835268-26-000019 |
| Document: 0001835268-26-000019-index.html | 0001835268-26-000019 |
| Document: 0001835268-26-000019.txt | 0001835268-26-000019 |
| 8-K Data (Synthetic) | 0001835268-26-000019 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | SC 13G | $0.9450 $0.9090 | ▼ −3.81% | ▼ −2.83% | $0.8425 (−10.85%) |
Sep 30, 2026 27d ago | 8-K | $1.10 $0.9450 | ▼ −14.09% | ▼ −16.00% | $0.8425 (−23.41%) |
Sep 30, 2026 27d ago | Press Release | $1.10 $0.9447 | ▼ −14.12% | ▼ −16.03% | $0.8425 (−23.41%) |
Sep 15, 2026 6w ago | 8-K | $1.17 $1.28 | ▲ +9.40% | ▲ +8.58% | $0.8425 (−27.99%) |
May 12, 2026 24w ago | 8-K | $2.68 $2.38 | ▼ −11.19% | ▼ −11.27% | $0.8425 (−68.56%) |
May 12, 2026 24w ago | Press Release | $2.68 $2.38 | ▲ +11.19% | ▲ +11.27% | $0.8425 (+68.56%) |
Apr 23, 2026 26w ago | 8-K | $2.52 $2.53 | ▲ +0.40% | ▼ −1.08% | $0.8425 (−66.57%) |
Mar 31, 2026 30w ago | 8-K | $2.72 $2.78 | ▲ +2.21% | ▼ −1.56% | $0.8425 (−69.03%) |
Mar 30, 2026 30w ago | Press Release | $2.90 $2.82 | ▼ −2.76% | ▼ −7.06% | $0.8425 (−70.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers